成人免费xx,国产又黄又湿又刺激不卡网站,成人性视频app菠萝网站,色天天天天

?????

?????
????? ??? ???
?? ??:
15307-86-5
???:
?????
???(??):
?????
???:
1-(2,6-Dichlorophenyl)-2-indolinone
???(??):
Diclofenac;Diciofenac;dichlofenac;DICLOFENAC FREE ACID;Pennsaid;Dichlofenac acid;Diclofenac (Aceclofenac EP Impurity A);Diclac;Rhumalgan;Voltaflan
CBNumber:
CB5225367
???:
C14H11Cl2NO2
??? ??:
296.15
MOL ??:
15307-86-5.mol
MSDS ??:
SDS

????? ??

???
156-158°
?? ?
412.0±45.0 °C(Predicted)
??
1.431±0.06 g/cm3(Predicted)
?? ??
Sealed in dry,Room Temperature
???
???? ???
??? ??
powder to crystal
?? ?? (pKa)
pKa 4 (Uncertain)
??
???? ?? ??
???
1.278mg/L(30℃)
Merck
14,3081
InChIKey
DCOPUUMXTXDBNB-UHFFFAOYSA-N
CAS ??????
15307-86-5(CAS DataBase Reference)
NIST
Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]-(15307-86-5)
EPA
Benzeneacetic acid, 2-[(2,6-dichlorophenyl)amino]- (15307-86-5)
??
  • ?? ? ?? ??
  • ?? ? ???? ?? (GHS)
????(UN No.) 3249
RTECS ?? AG6310000
HS ?? 2922.49.2600
?? ?? 6.1(b)
???? III
?? ?? ??? 15307-86-5(Hazardous Substances Data)
????(GHS): GHS hazard pictogramsGHS hazard pictogramsGHS hazard pictograms
?? ?: Danger
??·?? ??:
?? ??·?? ?? ?? ?? ?? ?? ? ?? ?? P- ??
H301 ??? ??? ?? ?? ?? - ?? ?? 3 ?? GHS hazard pictograms P264, P270, P301+P310, P321, P330,P405, P501
H372 ??? ?? ?? ???? ??(??, ??? ?? ??? ?? ??? ??)? ??? ??? ?? ???? ?? - ?? ?? ?? 1 ?? GHS hazard pictograms P260, P264, P270, P314, P501
H411 ??? ??? ?? ????? ??? ?? ????? ?? - ?? ?? 2
??????:
P202 ?? ?? ?? ??? ?? ???? ??? ???? ???.
P260 ??·?·??·???·??·...·????? ???? ???.
P264 ?? ??? ?? ??? ????.
P264 ?? ??? ?? ??? ????.
P270 ? ??? ??? ??? ???, ???? ???? ???.
P273 ???? ???? ???.
P301+P310 ???? ?? ????(??)? ??? ????.
NFPA 704
0
2 0

????? C??? ??, ??, ??

??

prostaglandin synthetic inhibitor

Indications

Diclofenac (Voltaren, Cataflam) is approved for use in rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, dysmenorrhea, and topically for the treatment treatment of ocular inflammation and actinic keratosis. Diclofenac exhibits approximately equal selectivity for COX-1 and COX-2. The most common adverse reactions are GI disturbances and headache.A reversible elevation of serum transaminases occurs in 15% of patients.

Biological Functions

Diclofenac (Voltaren) is a phenylacetic acid derivative that is a potent inhibitor of COX and that has analgesic, antiinflammatory, and antipyretic effects. Its use is accompanied by side effects similar to those of other NSAIDs. Indications for the drug include rheumatoid arthritis, osteoarthritis, and ophthalmic inflammation (use of an ophthalmic preparation).

Mechanism of action

Diclofenac is unique among the NSAIDs in that it possesses three possible mechanisms of action: 1) inhibition of the arachidonic acid cyclooxygenase system (3 to 1,000 times more potent than other NSAIDs on a molar basis), resulting in a decreased production of prostaglandins and thromboxanes; 2) inhibition of the lipoxygenase pathway, resulting in decreased production of leukotrienes, particularly the pro-inflammatory LKB4; and 3) inhibition of arachidonic acid release and stimulation of its reuptake, resulting in a reduction of arachidonic acid availability.

Pharmacokinetics

Diclofenac is rapidly and completely (~100%) absorbed on oral administration, with peak plasma levels being reached within 1.5 to 2.5 hours. The free acid (pKa = 4.0) is highly bound to serum proteins (99.5%), primarily albumin. Only 50 to 60% of an oral dose is bioavailable because of extensive hepatic metabolism.

Clinical Use

Diclofenac is synthesized from N-phenyl-2,6-dichloroaniline. It is available in 120 different countries and, perhaps, is the most widely used NSAID in the world. It was introduced in the United States in 1989 but was first marketed in Japan in 1974. It ranks among the top prescription drugs in the United States. Diclofenac possesses structural characteristics of both arylalkanoic acid and the anthranilic acid classes of anti-inflammatory drugs, and it displays anti-inflammatory, analgetic, and antipyretic properties.

?? ??

Four major metabolites resulting from aromatic hydroxylation have been identified. The major metabolite via CYP3A4 is the 4′-hydroxy derivative and accounts for 20 to 30% of the dose excreted, whereas the 5-hydroxy, 3′-hydroxy, and 4′,5-dihydroxy metabolites via CYP2C9 account for 10 to 20% of the excreted dose. The remaining drug is excreted in the form of sulfate conjugates. Although the major metabolite is much less active than the parent compound, it may exhibit significant biological activity, because it accounts for 30 to 40% of all of the metabolic products.

????? ?? ?? ? ???

???

?? ??


????? ?? ??

???( 421)?? ??
??? ?? ??? ?? ?? ? ??
Hebei Mojin Biotechnology Co., Ltd
+86 13288715578 +8613288715578
sales@hbmojin.com China 12835 58
Hebei Chuanghai Biotechnology Co,.LTD
+86-13131129325
sales1@chuanghaibio.com China 5893 58
Anhui Ruihan Technology Co., Ltd
+8617756083858
daisy@anhuiruihan.com China 973 58
Henan Fengda Chemical Co., Ltd
+86-371-86557731 +86-13613820652
info@fdachem.com China 20288 58
Hebei Zhuanglai Chemical Trading Co.,Ltd
+8613343047651
admin@zlchemi.com China 3002 58
Hebei Shengyang Water Conservancy Engineering Co., Ltd.
+8615373025980
clara@hbshengyang.com China 874 58
Henan Tianfu Chemical Co.,Ltd.
+86-0371-55170693 +86-19937530512
info@tianfuchem.com China 21637 55
career henan chemical co
+86-0371-86658258 +8613203830695
sales@coreychem.com China 29885 58
Hubei Jusheng Technology Co.,Ltd.
18871490254
linda@hubeijusheng.com CHINA 28172 58
Hebei Weibang Biotechnology Co., Ltd
+8615531157085
abby@weibangbio.com China 8816 58

????? ?? ??:

Copyright 2019 ? ChemicalBook. All rights reserved